CWR Bruce Bloom

2. The world’s first online
collaboration platform
repurposing research
25 project
repurposing research
portfolio
Social Finance
Initiative
Creating “pay for
success” repurposing
economics in the UK
5 Programs to Leverage Successes
and Overcome Challenges
The Low Profit Pharma Co.
Bringing low profit
commercializable generic
drug repurposing to market
with the support of Impact
Investors
The Generic Drug
Companies Initiative
Partner with generic drug companies
to fund generic drug repurposing
research based on potential overall
increases in the sales of generic
drugs.
Ongoing
Feasibility
Possibility

3. Feasibility-Low Profit Pharma Company
Huge Global Problem – Too many unsolved diseases, too few
therapeutic breakthroughs, the ones that come are too slow to
get to patients and too expensive.
Solution –Many therapeutic opportunities through generic drug
repurposing have huge financing challenges.
Innovation – create an investment vehicle for Impact Investors – a
low profit drug repurposing company to identify repurposing
opportunities across all disease classes that have potential
commercial return and patient impact, but are below industry
market returns.
Cures Within Reach is in an ideal position to do this work – we
have the platform, networks, experience and success stories.
CWR has already identified a set of repurposing projects that are
LoPro candidates.

4. Feasibility-Social Impact Bond Initiative
Problem-Industry does not fund generic drug
repurposing for current dosage and formulation
because there is little profit potential.
Solution-Create incentive for investors to finance life-
saving Repurposing Research through a Social Impact
Bond (SIB) in which the government pays for improved
healthcare outcomes and reduced healthcare costs
through drug repurposing.
CWR is currently developing this SIB concept with the
British Government and beginning to talk with the UN
and others about a global SIB initiative

5. Feasibility-Social Impact Bond Initiative

6. Feasibility-Social Impact Bond ROI
#of
clinical
trials
Average cost
perclinical
trial
Total
Rediscovery
ResearchCosts
Potential
success
rate
#of"new"
treatments
created
#ofpatients
whohave one
disease witha
"new
treatment
Projected
annual
healthcare $
saved/average
patient
Total potential 5
yearsavingsforall
patientswith
these diseases
%patients
actually
usingthe
"new"
treatments
healthcare $ saved
onthissub-
populationof
patientsAFTER
repayinginvestors
200 250,000 $50,000,000 10% 20 3000 $10,000 $600,000,000 10% $10,000,000
200 250,000 $50,000,000 15% 30 4000 $20,000 $2,400,000,000 10% $190,000,000
200 250,000 $50,000,000 20% 40 8000 $30,000 $9,600,000,000 10% $910,000,000
200 250,000 $50,000,000 25% 50 15000 $40,000 $30,000,000,000 10% $2,950,000,000
200 250,000 $50,000,000 30% 60 32000 $50,000 $96,000,000,000 10% $9,550,000,000

7. Possibility-The Generic Drug Companies
Repurposing Partnership
Economic Innovation – Partner with generic drug companies to
fund generic drug repurposing based increases in the sales of
generic drugs.
It makes sense –Every new repurposed generic drug use would
improve healthcare outcomes and increase revenue to generic
drug companies. The short-term investment is small and the long-
term return is large. CWR can promote off-label uses even if a
drug company cannot.
Generic drug companies information about off-label use of drugs
can inform researchers to propose additional repurposed uses.
This is a strong marketing/PR opportunity for generic drug
companies, showing their commitment to creating effective low
cost treatments for patients.

8. For more information, see
www.cureswithinreach.org
www.cureaccelerator.org
Twitter.com/CuresWReach
Facebook.com/P4Cures
Or contact:
Dr. Bruce Bloom
President and CSO
Bruce@cureswithinreach.org
847-745-1245